New hope for tough blood cancers: BT02 drug trial launches
NCT ID NCT07107204
First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tests a new drug called BT02 in people with blood cancers (leukemia, lymphoma, or multiple myeloma) that have returned or not improved with standard treatments. About 116 adults aged 18 to 70 will receive the drug by IV every 2-3 weeks for up to 2 years. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors or slow the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.